Cargando…

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borst, Gerben R., Kumareswaran, Ramya, Yücel, Hatice, Telli, Seyda, Do, Trevor, McKee, Trevor, Zafarana, Gaetano, Jonkers, Jos, Verheij, Marcel, O’Connor, Mark J., Rottenberg, Sven, Bristow, Robert G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675659/ https://www.ncbi.nlm.nih.gov/pubmed/29152107 http://dx.doi.org/10.18632/oncotarget.20936

Ejemplares similares

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2020)

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts
por: Lohse, Ines, et al.
Publicado: (2016)

Characterization of the radioresponse of human apical papilla-derived cells
por: Abe, Shigehiro, et al.
Publicado: (2011)

Characterizing the Radioresponse of Pluripotent and Multipotent Human Stem Cells
por: Lan, Mary L., et al.
Publicado: (2012)

Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse
por: Jackson, Isabel L., et al.
Publicado: (2016)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments
por: Lee, Ik Jae, et al.
Publicado: (2016)

Corrigendum: Pathophysiological mechanisms underlying phenotypic differences in pulmonary radioresponse
por: Jackson, Isabel L., et al.
Publicado: (2017)

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
por: Rottenberg, Sven, et al.
Publicado: (2012)

Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma
por: Xu, Xin, et al.
Publicado: (2022)

Tumor hypoxia as a driving force in genetic instability
por: Luoto, Kaisa R, et al.
Publicado: (2013)

Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells
por: Brandt, Florian, et al.
Publicado: (2022)

Establishment of a 3D Model to Characterize the Radioresponse of Patient-Derived Glioblastoma Cells
por: Strand, Zoe, et al.
Publicado: (2023)

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids
por: Paes Dias, Mariana, et al.
Publicado: (2022)

Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase
por: Berge, D L Van den, et al.
Publicado: (2001)

Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling
por: Ko, A, et al.
Publicado: (2014)

Identifying Long Non-coding RNA of Prostate Cancer Associated With Radioresponse by Comprehensive Bioinformatics Analysis
por: Xu, Meng, et al.
Publicado: (2020)

Fluctuation in radioresponse of HeLa cells during the cell cycle evaluated based on micronucleus frequency
por: Shimono, Hiroaki, et al.
Publicado: (2020)

EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
por: Zander, Serge A. L., et al.
Publicado: (2012)

Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie!
por: Zafarana, Gaetano, et al.
Publicado: (2010)

Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy
por: Zhang, Yimin, et al.
Publicado: (2014)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Li, Yu, et al.
Publicado: (2021)

Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia
por: Zhu, Hongcheng, et al.
Publicado: (2015)

StemRegenin 1 Mitigates Radiation-Mediated Hematopoietic Injury by Modulating Radioresponse of Hematopoietic Stem/Progenitor Cells
por: Hwang, You Jung, et al.
Publicado: (2023)

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
por: Hongthong, Khwanjira, et al.
Publicado: (2021)

Tumor Growth Suppression and Enhanced Radioresponse by an Exogenous Epidermal Growth Factor in Mouse Xenograft Models with A431 Cells
por: Lim, Yu Jin, et al.
Publicado: (2015)

Danshensu, a major water-soluble component of Salvia miltiorrhiza, enhances the radioresponse for Lewis Lung Carcinoma xenografts in mice
por: Cao, Hong-Ying, et al.
Publicado: (2017)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Unique epigenetic influence of H2AX phosphorylation and H3K56 acetylation on normal stem cell radioresponses
por: Jacobs, Keith M., et al.
Publicado: (2016)

A Radioresponse-Related lncRNA Biomarker Signature for Risk Classification and Prognosis Prediction in Non-Small-Cell Lung Cancer
por: Song, Jiahang, et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

NF-κB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase
por: Ridder, M De, et al.
Publicado: (2003)

A novel 3D pillar/well array platform using patient-derived head and neck tumor to predict the individual radioresponse
por: Lee, Dong Woo, et al.
Publicado: (2022)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
por: Wang, Shu-Ping, et al.
Publicado: (2021)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e0u6vhr61a46tfipjcea045297